1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation.
The vitamin D receptor (VDR) from a variety of animal species is a hormone-modulated substrate for phosphorylation in vivo. In this report, we utilize an expression vector to produce recombinant human VDR (hVDR) in 1,25-dihydroxyvitamin D3-treated COS-1 cells. Immunoprecipitation of the phosphorylated hVDR followed by gel purification and phosphoamino acid analysis revealed modification exclusively on one or more serine residues, consistent with previous studies of the VDR in other species. To identify the region of phosphorylation, immunoprecipitated and gel-purified hVDR from COS-1 cells was first mixed with purified hVDR isolated to homogeneity from Saccharomyces cerevisiae and then digested with trypsin or V8 protease, and the peptides were resolved on HPLC. The single phosphate-containing peptides were recovered and subjected to amino acid sequence analysis, revealing the modification to reside in a region extending from residue 171 to residue 206 common to both the tryptic- and the V8 protease-derived peptides. Sequential cleavage of similar VDR mixtures using trypsin and then CNBr, alpha-chymotrypsin, or thermolysin demonstrated an amino-terminal boundary of the phosphorylated peptide at 202. Selective manual Edman degradation of phosphorylated peptides beginning at 171, 195, and 200 revealed phosphate release only at serine 205. This peptide contained an average of 8-fold less radioactive phosphate in the absence of prior treatment of the culture cells with 1,25(OH)2D3. Site-directed modification of VDR serine 205 to alanine, aspartate, or glutamate each led to fully functional proteins when assessed in a transactivation assay using several VDRE-linked natural promoters. Unexpectedly, evaluation of the serine 205 to alanine hVDR mutant revealed that this protein continued to be phosphorylated in a hormone-dependent manner on an alternative site. These studies show directly that hVDR serine residue 205, a consensus site for casein kinase II, is modified in vivo in response to hormone.
Hilliard
G M
GM
Department of Biochemistry, Ligand Pharmaceuticals Inc., San Diego, California 92121.
Cook
R G
RG
Weigel
N L
NL
Pike
J W
JW
D000595:Amino Acid Sequence; D000818:Animals; D002117:Calcitriol / Q000378:metabolism*; D002461:Cell Line, Transformed; D002522:Chlorocebus aethiops; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000302:isolation & purification / Q000378:metabolism; D010449:Peptide Mapping; D010766:Phosphorylation; D018167:Receptors, Calcitriol / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012694:Serine / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
D010446:Peptide Fragments; D018167:Receptors, Calcitriol; D011994:Recombinant Proteins; D012694:Serine; D002117:Calcitriol